Cladribine is a purine nucleoside analog used to treat hairy cell leukemia and multiple sclerosis by interfering with DNA synthesis, leading to cell death. It is grouped under the following drug class(es): Antineoplastic agents, Cytotoxics and Nucleosides. Its therapeutic use is listed as anti-cancer agents, antineoplastics and multiple sclerosis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Leustatin and Mavenclad. Its PubChem CID is 20279.
Cladribine
| CAS No | 4291-63-8 |
|---|---|
| Molecular Formula | C10H12ClN5O3 |
| Molecular Weight | 285.69 g/mol |
| Synonyms | (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Cladribine is a purine nucleoside analog used to treat hairy cell leukemia and multiple sclerosis by interfering with DNA synthesis, leading to cell death. It is grouped under the following drug class(es): Antineoplastic agents, Cytotoxics and Nucleosides.
The listed CAS number is 4291-63-8.
The listed molecular formula is C10H12ClN5O3.
The listed molecular weight is 285.69 g/mol.
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol.
The source lists Leustatin and Mavenclad.